Home » Stocks » HSTO

Histogen, Inc. (HSTO)

Stock Price: $1.03 USD -0.07 (-6.36%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 36.82M
Revenue (ttm) 2.06M
Net Income (ttm) -18.77M
Shares Out 9.02M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.03
Previous Close $1.10
Change ($) -0.07
Change (%) -6.36%
Day's Open 1.07
Day's Range 1.02 - 1.07
Day's Volume 994,082
52-Week Range 0.32 - 5.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

3 weeks ago - GlobeNewsWire

Topline Results Expected in the Second Quarter of 2021 Topline Results Expected in the Second Quarter of 2021

1 month ago - GlobeNewsWire

Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises

1 month ago - GlobeNewsWire

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

1 month ago - GlobeNewsWire

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

1 month ago - GlobeNewsWire

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

2 months ago - GlobeNewsWire

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that...

3 months ago - PRNewsWire

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...

3 months ago - GlobeNewsWire

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...

3 months ago - GlobeNewsWire

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publi...

Other stocks mentioned: CNAT
11 months ago - GlobeNewsWire

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the ...

Other stocks mentioned: CNAT
11 months ago - GlobeNewsWire

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockho...

Other stocks mentioned: CNAT
11 months ago - GlobeNewsWire

SAN DIEGO, April 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it...

Other stocks mentioned: CNAT
11 months ago - GlobeNewsWire

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the pub...

Other stocks mentioned: CNAT
1 year ago - GlobeNewsWire

Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021

Other stocks mentioned: CNAT
1 year ago - GlobeNewsWire

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, CNAT, GLMD, ICPT, MDGL
1 year ago - Zacks Investment Research

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional indepen...

Other stocks mentioned: CNAT
1 year ago - GlobeNewsWire

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close.

Other stocks mentioned: CNAT
1 year ago - Benzinga

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Other stocks mentioned: CNAT
1 year ago - Zacks Investment Research

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?

Other stocks mentioned: CNAT
2 years ago - Zacks Investment Research

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

Other stocks mentioned: AGN, CNAT, GILD, ICPT, MRK, NVS
2 years ago - Zacks Investment Research

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

Other stocks mentioned: CNAT
2 years ago - Zacks Investment Research

Shares of microcap biotech Conatus Pharmaceuticals Inc. are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate.

Other stocks mentioned: CNAT
2 years ago - Benzinga

Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

Other stocks mentioned: CNAT
2 years ago - Zacks Investment Research

Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

Other stocks mentioned: CNAT
2 years ago - Zacks Investment Research

About HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of ... [Read more...]

Industry
Biotechnology
CEO
Steven Mento
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
HSTO
Full Company Profile

Financial Performance

In 2020, Histogen's revenue was $2.06 million, a decrease of -82.02% compared to the previous year's $11.45 million. Losses were -$18.77 million, 532.8% more than in 2019.

Financial Statements